Overview Financials News + Filings IR Vault Key Docs Charts Ownership Insiders
All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Asset disposition
Quarterly results
Acq. announced
Appointed director
|
|
NITROMED INC (NTMD)
|
Create: Alert |
All | News | Filings
| Date Filed | Type | Description |
| 03/19/2009 |
8-K
| Form 8-K -- Current report |
| 10/23/2008 |
8-K
| Quarterly results|
Docs:
|
"Purchase and Sale Agreement, by and between NitroMed, Inc. and JHP Pharmaceuticals, LLC",
"VOTING AGREEMENT This VOTING AGREEMENT is entered into as of October 22, 2008, by and among NitroMed, Inc., a Delaware corporation , and HealthCare Ventures, Rho Ventures and Invus Public Equities, L.P. and JHP Pharmaceuticals, LLC, a Delaware limited liability company . INTRODUCTION A. Concurrently with the execution and delivery of this Agreement, Seller and Buyer are entering into a Purchase and Sale Agreement pursuant to which, among other things, Seller shall sell, convey, assign, transfer and deliver to Buyer, and Buyer shall purchase and acquire from Seller, all of Seller's right, title and interest in and to all of the Acquired Assets, free and clear of any and all Security Interests, and Buyer shall assume from Seller and be responsible for the Assumed Liabilities. Capitalized ter...",
"NitroMed Announces Agreement to Sell BiDil® Drug Business to JHP Pharmaceuticals, LLC —NTMD Reports Financial Results for Third Fiscal Quarter 2008" |
|
| 08/05/2008 |
8-K
| Quarterly results |
| 05/07/2008 |
8-K
| Quarterly results |
| 02/14/2008 |
8-K
| Quarterly results|
Docs:
|
"NitroMed Reports Financial Results for Fourth Quarter and Full Year 2007 - Conference Call and Webcast Today at 9:00 AM EST- LEXINGTON, MA——NitroMed, Inc. today reported financial results for the fourth quarter and the year ended December 31, 2007. Total revenues for the three months ended December 31, 2007 were $5.0 million compared to $3.5 million for the same period in 2006. BiDil revenues for the fourth quarter were $4.2 million, an increase of $0.7 million, or 21%, over the comparable 2006 period. For the year ended December 31, 2007, the Company reported total revenues of $16.0 million compared to $12.1 million for the same period in 2006, an increase of $3.9 million, or 33%. BiDil accounted for $15.3 million in revenues for the year ended December 31, 2007, representing a $3.2 milli..." |
|
| 10/31/2007 |
8-K
| Quarterly results|
Docs:
|
"NitroMed Reports Financial Results for Third Quarter 2007 - Conference Call and Webcast Today at 8:30 AM EDT - LEXINGTON, MA——NitroMed, Inc. , an emerging pharmaceutical company and the maker of BiDil , an orally administered medicine approved in the United States for the treatment of heart failure in self-identified black patients, today reported financial results for its third fiscal quarter and year to date ended September 30, 2007. Total revenues for the three months ended September 30, 2007 were $3.8 million compared to $3.4 million for the same period in 2006, an increase of $0.4 million or 10%. For the nine months ended September 30, 2007, total revenues were $11.0 million, compared to $8.6 million for the same period during 2006, an increase of $2.4 million, or 28%. Sales of BiDil ..." |
|
| 08/01/2007 |
8-K
| Quarterly results |
| 05/02/2007 |
8-K
| Quarterly results |
| 03/08/2007 |
8-K
| Quarterly results|
Docs:
|
"NitroMed Reports Financial Results for Fourth Quarter and Full Year 2006 - Conference Call and Webcast to be Held Today at 4:30 PM ET- LEXINGTON, MA——NitroMed, Inc. today reported financial results for the fourth quarter and the year ended December 31, 2006. Total revenues for the three months ended December 31, 2006 were $3.5 million compared to $3.7 million for the same period in 2005, a decrease of $0.2 million. BiDil® revenues for the fourth quarter were also $3.5 million, an increase of $0.2 million over the comparable 2005 period. For the year ended December 31, 2006, the Company reported total revenues of $12.1 million compared to $6.0 million for the same period in 2005, an increase of $6.1 million or just over 100%. All revenues for the full year ended December 31, 2006 came from ..." |
|
| 11/02/2006 |
8-K
| Quarterly results|
Docs:
|
"NitroMed Reports Financial Results for Third Quarter 2006 - Conference Call and Webcast Today at 4:00 PM ET- LEXINGTON, Mass — November 2, 2006—NitroMed, Inc. today reported financial results for the three- and nine-month periods ended September 30, 2006. Total revenue for the three-month period ended September 30, 2006 was $3.4 million compared to $1.5 million for the same period in 2005, an increase of $1.9 million. Total revenue for the nine-month period ended September 30, 2006 was $8.6 million compared to $2.3 million for the same period in 2005, an increase of $6.3 million. Net sales of BiDil® accounted for all of the Company's revenue during the first nine months of 2006, and $1.1 million of the Company's revenue during the three and nine-month periods ended September 30, 2005. Lice..." |
|
| 08/03/2006 |
8-K
| Quarterly results |
| 05/02/2006 |
8-K
| Quarterly results |
| 03/02/2006 |
8-K
| Quarterly results|
Docs:
|
"NitroMed Reports Financial Results for Fourth Quarter and Full Year 2005 - Conference Call and Webcast to be Held Today at 9:00 AM ET- LEXINGTON, Mass—March 2, 2006—NitroMed, Inc. today reported financial results for the fourth quarter and the year ended December 31, 2005. Total revenue for the three months ended December 31, 2005 was $3.7 million compared to $9.5 million for the same period in 2004, a decrease of $5.7 million. For the year ended December 31, 2005, the Company reported total revenue of $6.0 million compared to $16.5 million for the same period in 2004, a decrease of $10.4 million. Of total revenue, BiDil product sales accounted for $3.3 million during the fourth quarter, $4.5 million for the year ended December 31, 2005 and none during 2004. The decrease in total revenue i..." |
|
| 11/03/2005 |
8-K
| Quarterly results |
| 08/03/2005 |
8-K
| Quarterly results|
Docs:
|
"NitroMed, Inc. Reports Financial Results for Second Quarter 2005 -Conference Call August 3 at 5:00 PM EDT- Lexington, MA, August 3, 2005 - NitroMed, Inc. , a developer of nitric oxide enhancing medicines, including BiDil , today reported financial results for the second quarter ended June 30, 2005. Total revenue for the three months ended June 30, 2005 was $0.4 million compared to $2.3 million for the three months ended June 30, 2004, a decrease of $1.9 million, or 83%. For the six months ended June 30, 2005 revenue totaled $0.8 million compared to $4.7 million for the six months ended June 30, 2004, a decrease of $3.9 million, or 83%. The decrease in revenue in both the three and six month periods ended June 30, 2005 is primarily attributable to the termination of our collaboration agreem..." |
|
|
|